Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study.
Latest Information Update: 05 May 2017
At a glance
- Drugs Topiramate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Acronyms PREVAIL OLE
- Sponsors Upsher-Smith
- 28 Apr 2017 Results assessing efficacy and safety of USL255 and other second-generation antiepileptic drugs using patient data from PREVAIL, PREVAIL OLE and one more study (Guberman et al, 2002), presented at the 69th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Results of pooled analysis from three phase I and two phase III studies assessing the differentiating features of Topiramate (extented release capsules and immediate release) presented at the 68th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Post-hoc efficacy analysis of this PREVAIL OLE trial were presented at the 68th Annual Meeting of the American Academy of Neurology.